Arcus Biosciences
RCUS
209 hedge funds and large institutions have $2.89B invested in Arcus Biosciences in 2025 Q4 according to their latest regulatory filings, with 48 funds opening new positions, 95 increasing their positions, 38 reducing their positions, and 27 closing their positions.
1,666% more call options, than puts
Call options by funds: $92.8M | Put options by funds: $5.26M
150% more repeat investments, than reductions
Existing positions increased: 95 | Existing positions reduced: 38
112% more capital invested
Capital invested by funds: $1.37B → $2.89B (+$1.53B)
100% more funds holding in top 10
Funds holding in top 10: 2 → 4 (+2)
78% more first-time investments, than exits
New positions opened: 48 | Existing positions closed: 27
17.94% more ownership
Funds ownership: 94.53% → 112.48% (+18%)
10% more funds holding
Funds holding: 190 → 209 (+19)
Top Buyers
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$79.9M |
| 2 |
Marshall Wace
London,
United Kingdom
|
+$69.1M |
| 3 |
BlackRock
New York
|
+$65M |
| 4 |
SC
Samlyn Capital
New York
|
+$32.7M |
| 5 |
SCM
Suvretta Capital Management
New York
|
+$30.6M |
Top Sellers
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$23.7M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$21.5M |
| 3 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$15.5M |
| 4 |
Millennium Management
New York
|
-$9.51M |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$7.34M |
RCUS Hedge Fund Activity: Q4 2025 in Review
209 of the 8,223 institutional investors tracked by Wall St. Rank reported a position in Arcus Biosciences (RCUS) for Q4 2025, worth a combined $2.89B — up 112% from $1.37B a quarter earlier.
Buyers outnumbered sellers: 48 funds opened new RCUS positions and 27 closed out — a net gain of 21 holders — while 95 added to existing stakes and 38 trimmed.
The largest buyer was Wellington Management Group, adding an estimated $79.9M. The largest seller was Fidelity Investments, cutting an estimated $23.7M.
- 209 institutional investors held Arcus Biosciences (RCUS) as of Q4 2025, up from 190 in Q3 2025.
- Funds reported $2.89B of Arcus Biosciences stock for Q4 2025, up 112% quarter-over-quarter.
- 48 funds opened new Arcus Biosciences positions in Q4 2025 and 27 closed out, a net change of +21 holders.
- The largest Arcus Biosciences buyer in Q4 2025 was Wellington Management Group, an estimated $79.9M added.
- The largest Arcus Biosciences seller in Q4 2025 was Fidelity Investments, an estimated $23.7M sold.
Based on aggregated 13F filings for Q4 2025.